v3.25.1
LIQUIDITY (Details) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Apr. 24, 2025
Apr. 23, 2025
Jun. 24, 2024
Apr. 30, 2025
Jul. 31, 2024
Jun. 30, 2024
Apr. 30, 2024
Mar. 31, 2025
Mar. 31, 2024
Mar. 31, 2025
Mar. 31, 2024
Jun. 30, 2024
Jun. 17, 2024
Accumulated deficit           $ 329,444   $ 379,466   $ 379,466   $ 329,444  
Net loss               18,914 $ 17,050 50,022 $ 45,483 68,500  
Net cash used in operating activities                   47,080 $ 38,846 57,400  
Cash and cash equivalents           70,396   14,596   14,596   70,396  
Short-term investments           56,478   72,296   72,296   56,478  
Long-term investments           263   1,514   1,514   263  
Total liabilities           11,734   12,170   12,170   11,734  
Current liabilities           $ 9,606   $ 10,527   10,527   $ 9,606  
Private Placement                          
Number of shares issued         1,500,000 1,500,000              
Shares issue price           $ 4           $ 4  
Sale of stock received on transaction         $ 6,000                
Underwritten Public Offering                          
Number of shares issued     11,250,000                    
Shares issue price     $ 4                    
Net cash proceeds     $ 62,600                    
Underwritten Public Offering | Subsequent Event                          
Number of shares issued   20,786,923   24,940,769                  
Shares issue price   $ 3.25   $ 3.25                  
Net cash proceeds $ 96,900     $ 96,900                  
Underwritten Public Offering | Pre Funded Warrants 2024                          
Shares issue price     $ 3.999                    
Pre-funded warrants to purchase shares of common stock     3,750,000                   3,750,000
Underwritten Public Offering | Pre Funded Warrants 2025 | Subsequent Event                          
Shares issue price   $ 3.249   $ 3.249                  
Pre-funded warrants to purchase shares of common stock   6,905,385   6,905,385                  
XOMA (US) LLC | Phase 3 Clinical Trial RZ 358 (ersodetug) | Xoma License Agreement                          
Milestone closing payment             $ 5,000            
XOMA (US) LLC | Phase 3 Clinical Trial RZ 358 (ersodetug) | Xoma License Agreement | Scenario, Upon Dosing Of The Last Patient                          
Milestone closing payment                   $ 5,000